Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 6Phase 3 3Phase 2/3 3Phase 1/2 2Phase EARLY_PHASE1 1Phase 4 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Genitourinary 1Endocrine 1Dermatologic 1CNS 1

Conditions

Wilms Tumor 1Uveal Melanoma 1Thyroid Cancer, Papillary 1Sarcoma, Ewing 1Sarcoma 1Salivary Gland Neoplasms 1Recurrence 1Neuroblastoma 1Nephroma, Mesoblastic 1Neoplasm Metastasis 1Medulloblastoma 1Glioma 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × entrectinib × Clear all
NCT02650401 2026-03-25

STARTRK-NG

Hoffmann-La Roche

Phase 1/2 Active not recruiting
69 enrolled 1 FDA
CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT04589832 2023-11-22

Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

Hoosier Cancer Research Network

Phase 1/2 Terminated
6 enrolled 9 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡